Collegium Pharmaceutical (NASDAQ:COLL) Trading 2.8% Higher - Should You Buy?

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) shot up 2.8% during trading on Wednesday . The stock traded as high as $30.00 and last traded at $29.97. 25,883 shares were traded during mid-day trading, a decline of 93% from the average session volume of 368,973 shares. The stock had previously closed at $29.14.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on COLL. StockNews.com lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Collegium Pharmaceutical currently has an average rating of "Moderate Buy" and an average price target of $42.60.

Collegium Pharmaceutical Stock Up 14.4 %

The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of 14.37 and a beta of 0.82. The firm's 50-day simple moving average is $30.61 and its two-hundred day simple moving average is $34.05. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds have recently bought and sold shares of COLL. JPMorgan Chase & Co. lifted its position in Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock valued at $10,711,000 after buying an additional 175,892 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock worth $67,459,000 after acquiring an additional 64,958 shares in the last quarter. Franklin Resources Inc. grew its stake in Collegium Pharmaceutical by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company's stock valued at $1,164,000 after purchasing an additional 3,620 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in Collegium Pharmaceutical by 10.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company's stock worth $695,000 after purchasing an additional 1,731 shares during the last quarter. Finally, TD Private Client Wealth LLC raised its position in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock valued at $66,000 after purchasing an additional 483 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.